The effect of mannitol on cerebral blood flow.
The objective of this study was to evaluate the effects of mannitol, given over different time periods, on regional cerebral blood flow (rCBF) in patients with intracranial aneurysms. Seven patients with unruptured aneurysms (Group I) and 16 patients with Grade I and II subarachnoid hemorrhage (SAH) (Group II) received 1.5 gm/kg/8 hrs of 20% mannitol intravenously over a 24-hour period. Seven other patients with unruptured aneurysms (Group III) received 1.5 gm/kg of mannitol over 8 hours only. The last seven patients with unruptured aneurysms (Group IV) received the same dose, but as an intravenous bolus. Over a period of 24 hours, the patients underwent serial measurements of rCBF, intracranial pressure (ICP), mean blood pressure (MBP), cardiac output, and cerebral metabolic rate of oxygen consumption (CMRO2). Mannitol, when given as a continuous intravenous infusion, increased rCBF significantly without increasing MBP or decreasing ICP. This increase was more pronounced in SAH patients. The effects of mannitol lasted for 18 hours when given over an 8-hour period only; however, when it was given as a bolus, the increase in rCBF lasted for 24 hours, cardiac output tended to increase, and the effect on CMRO2 was variable.
D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D006801:Humans; D002532:Intracranial Aneurysm / Q000188:drug therapy* / Q000503:physiopathology; D007427:Intracranial Pressure / Q000187:drug effects; D008353:Mannitol / Q000494:pharmacology / Q000627:therapeutic use*; D010101:Oxygen Consumption / Q000187:drug effects; D013345:Subarachnoid Hemorrhage / Q000188:drug therapy* / Q000503:physiopathology
D008353:Mannitol